Sonoma Pharmaceuticals Inc (NASDAQ:SNOA)’s share price traded down 0.3% during mid-day trading on Friday . The stock traded as low as $3.05 and last traded at $3.11. 1,058 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 75,899 shares. The stock had previously closed at $3.12.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a report on Thursday, April 5th. ValuEngine raised shares of Sonoma Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Maxim Group cut shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 price objective on the stock. in a research report on Monday, March 5th.
The stock has a market cap of $14.99 million, a P/E ratio of -0.92 and a beta of 1.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.83 and a current ratio of 4.62.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings data on Wednesday, June 13th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.34). The company had revenue of $3.66 million during the quarter, compared to the consensus estimate of $4.51 million. Sonoma Pharmaceuticals had a negative net margin of 86.01% and a negative return on equity of 87.71%. equities analysts predict that Sonoma Pharmaceuticals Inc will post -2.2 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of SNOA. Sabby Management LLC bought a new stake in Sonoma Pharmaceuticals in the 1st quarter valued at $255,000. Deutsche Bank AG bought a new stake in Sonoma Pharmaceuticals in the 4th quarter valued at $137,000. Finally, Renaissance Technologies LLC lifted its position in Sonoma Pharmaceuticals by 58.7% in the 4th quarter. Renaissance Technologies LLC now owns 58,602 shares of the company’s stock valued at $319,000 after acquiring an additional 21,680 shares in the last quarter. 15.66% of the stock is currently owned by institutional investors and hedge funds.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.